MAP2K7 and melanoma: The trial of LGX818 (COLUMBUS) is currently underway, assessing the efficacy of the combination of LGX818 and MEK inhibitor MEK162 and LGX818 monotherapy versus vemurafenib alone in advanced melanoma harboring V600 mutation [47].